Herling Suzanne Forsyth, Dreijer Bjørn, Wrist Lam Gitte, Thomsen Thordis, Møller Ann Merete
Department of Anaesthesiology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev Ringvej 75, Herlev, Denmark, 2730.
Department of Urology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev ringvej, Herlev, Denmark, 2710.
Cochrane Database Syst Rev. 2017 Apr 4;4(4):CD011387. doi: 10.1002/14651858.CD011387.pub2.
Rapid implementation of robotic transabdominal surgery has resulted in the need for re-evaluation of the most suitable form of anaesthesia. The overall objective of anaesthesia is to minimize perioperative risk and discomfort for patients both during and after surgery. Anaesthesia for patients undergoing robotic assisted surgery is different from anaesthesia for patients undergoing open or laparoscopic surgery; new anaesthetic concerns accompany robotic assisted surgery.
To assess outcomes related to the choice of total intravenous anaesthesia (TIVA) or inhalational anaesthesia for adults undergoing transabdominal robotic assisted laparoscopic gynaecological, urological or gastroenterological surgery.
We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2016 Issue 5), Ovid MEDLINE (1946 to May 2016), Embase via OvidSP (1982 to May 2016), the Cumulative Index to Nursing and Allied Health Literature (CINAHL) via EBSCOhost (1982 to May 2016) and the Institute for Scientific Information (ISI) Web of Science (1956 to May 2016). We also searched the International Standard Randomized Controlled Trial Number (ISRCTN) Registry and Clinical trials gov for ongoing trials (May 2016).
We searched for randomized controlled trials (RCTs) including adults, aged 18 years and older, of both genders, treated with transabdominal robotic assisted laparoscopic gynaecological, urological or gastroenterological surgery and focusing on outcomes of TIVA or inhalational anaesthesia.
We used standard methodological procedures of Cochrane. Study findings were not suitable for meta-analysis.
We included three single-centre, two-arm RCTs involving 170 participants. We found one ongoing trial. All included participants were male and were undergoing radical robotic assisted laparoscopic radical prostatectomy (RALRP). The men were between 50 and 75 years of age and met criteria for American Society of Anesthesiologists physical classification scores (ASA) I, ll and III.We found evidence showing no clinically meaningful differences in postoperative pain between the two types of anaesthetics (mean difference (MD) in visual analogue scale (VAS) scores at one to six hours was -2.20 (95% confidence interval (CI) -10.62 to 6.22; P = 0.61) in a sample of 62 participants from one study. Low-quality evidence suggests that propofol reduces postoperative nausea and vomiting (PONV) over the short term (one to six hours after surgery) after RALRP compared with inhalational anaesthesia (sevoflurane, desflurane) (MD -1.70, 95% CI -2.59 to -0.81; P = 0.0002).We found low-quality evidence suggesting that propofol may prevent an increase in intraocular pressure (IOP) after pneumoperitoneum and steep Trendelenburg positioning compared with sevoflurane (MD -3.90, 95% CI -6.34 to -1.46; P = 0.002) with increased IOP from baseline to 30 minutes in steep Trendelenburg. However, it is unclear whether this surrogate outcome translates directly to clinical avoidance of ocular complications during surgery. No studies addressed the secondary outcomes of adverse effects, all-cause mortality, respiratory or circulatory complications, cognitive dysfunction, length of stay or costs. Overall the quality of evidence was low to very low, as all studies were small, single-centre trials providing unclear descriptions of methods.
AUTHORS' CONCLUSIONS: It is unclear which anaesthetic technique is superior - TIVA or inhalational - for transabdominal robotic assisted surgery in urology, gynaecology and gastroenterology, as existing evidence is scarce, is of low quality and has been generated from exclusively male patients undergoing robotic radical prostatectomy.An ongoing trial, which includes participants of both genders with a focus on quality of recovery, might have an impact on future evidence related to this topic.
机器人经腹手术的迅速开展使得有必要重新评估最合适的麻醉方式。麻醉的总体目标是将患者手术期间及术后的围手术期风险和不适降至最低。接受机器人辅助手术患者的麻醉与接受开放手术或腹腔镜手术患者的麻醉不同;机器人辅助手术带来了新的麻醉问题。
评估在接受经腹机器人辅助腹腔镜妇科、泌尿外科或胃肠外科手术的成人中,选择全静脉麻醉(TIVA)或吸入麻醉的相关结局。
我们检索了Cochrane对照试验中心注册库(CENTRAL;2016年第5期)、Ovid MEDLINE(1946年至2016年5月)、通过OvidSP检索的Embase(1982年至2016年5月)、通过EBSCOhost检索的护理学与健康相关文献累积索引(CINAHL)(1982年至2016年5月)以及科学信息研究所(ISI)的科学引文索引(1956年至2016年5月)。我们还检索了国际标准随机对照试验编号(ISRCTN)注册库和Clinical trials gov以查找正在进行的试验(2016年5月)。
我们检索了随机对照试验(RCT),纳入年龄在18岁及以上的成年男女,接受经腹机器人辅助腹腔镜妇科、泌尿外科或胃肠外科手术,并关注TIVA或吸入麻醉的结局。
我们采用了Cochrane的标准方法程序。研究结果不适合进行Meta分析。
我们纳入了三项单中心、双臂RCT,涉及170名参与者。我们发现一项正在进行的试验。所有纳入的参与者均为男性,正在接受机器人辅助腹腔镜根治性前列腺切除术(RALRP)。这些男性年龄在50至75岁之间,符合美国麻醉医师协会身体状况分级评分(ASA)I、II和III标准。我们发现有证据表明,在一项研究的62名参与者样本中,两种麻醉方式术后疼痛无临床意义上的差异(1至6小时视觉模拟量表(VAS)评分的平均差(MD)为-2.20(95%置信区间(CI)-10.62至6.22;P = 0.61)。低质量证据表明,与吸入麻醉(七氟醚、地氟醚)相比,丙泊酚在RALRP术后短期内(术后1至6小时)可减少术后恶心呕吐(PONV)(MD -1.70,95% CI -2.59至-0.81;P = 0.0002)。我们发现低质量证据表明,与七氟醚相比,丙泊酚在气腹和头低脚高位倾斜后可能预防眼内压(IOP)升高(MD -3.90,95% CI -6.34至-1.46;P = 0.002),在头低脚高位倾斜时IOP从基线升高至30分钟。然而,尚不清楚这一替代结局是否能直接转化为手术期间临床避免眼部并发症。没有研究涉及不良反应、全因死亡率、呼吸或循环并发症、认知功能障碍、住院时间或费用等次要结局。总体而言,证据质量低至极低,因为所有研究均为小型单中心试验,对方法的描述不清晰。
对于泌尿外科、妇科和胃肠科的经腹机器人辅助手术,尚不清楚哪种麻醉技术更优——TIVA还是吸入麻醉,因为现有证据稀缺、质量低,且仅来自接受机器人根治性前列腺切除术 的男性患者。一项正在进行的试验纳入了男女参与者并关注恢复质量,可能会对与该主题相关的未来证据产生影响。